Physician profile
Michael Stadiem
NPI 1750342168
$6,454.87
in general payments reported to CMS, 2019-2025
45 companies · $837 in 2025
The $837 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $699 · 2021: $1,215 · 2022: $1,407 · 2023: $844 · 2024: $775 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,456.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,074.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $637.19 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $512.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $468.88 | 2021-2025 | Vraylar, Viberzi |
| Glaxosmithkline, LLC. | $356.76 | 2020-2023 | Arexvy, Shingrix |
| Amgen INC. | $204.48 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.42 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $143.81 | 2022-2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $143.51 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Takeda Pharmaceuticals U.S.A., INC. | $138.37 | 2019-2022 | |
| Pfizer INC. | $134.93 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $106.32 | 2019-2021 | |
| Daiichi Sankyo INC. | $96.61 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $88.98 | 2022 | |
| Exact Sciences Corporation | $88.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stadiem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.